Immunosuppressive Activity of 13-cis-Retinoic Acid and Prevention of Experimental Autoimmune Encephalomyelitis in Rats

Luca Massacesi, Emanuela Castiglioni, Marco Vergelli, Jacopo Olivotto, Anna Laura Abbaamondi,* Francesco Sarlo, and Luigi Amaducci
Dipartimento di Scienze Neurologiche e Psichiatiche Università degli Studi di Firenze, 50134 Florence, Italy; *Istituto di Neurologia, Università Cattolica, Policlinico Gemelli, 00100 Rome, Italy

Abstract

Some activities of retinoids on cellular and humoral immunity have been described, but the available data are conflicting or obtained at concentrations that are toxic in vivo. In this study, we demonstrate that 13-cis-retinoic acid (13-cRA), a retinoid well tolerated in human therapy, can suppress T cell–mediated immunity in rats. Treatment with pharmacological concentrations of 13-cRA prevented active as well as passive transfer experimental autoimmune encephalomyelitis (EAE) and suppressed lymphocyte responsiveness to T cell mitogens, suggesting that the drug activity included suppression of an effector T cell response. In addition, mitogen- and antigen-induced lymphocyte proliferation was inhibited in vitro in the presence of concentrations of 13-cRA equivalent to or less than those achieved in vivo, further suggesting that the prevention of EAE was due to a suppressive activity on T cell–mediated immunity. The immunosuppressive activity of 13-cRA included suppression of interleukin 2, whose production was inhibited in splenocytes. These data indicate that, in an in vivo mammalian system, 13-cRA exerts a suppressive activity on T cell–mediated immunity intensive enough to suppress an ongoing immune response, and that this effect can be achieved at nontoxic concentrations that may also be attained in human therapy. (J. Clin. Invest. 1991. 88:1331–1337.) Key words: experimental autoimmune encephalomyelitis • central nervous system • isotretinoin • T cell–mediated immunity • immunotherapy

Introduction

Retinoids are the class of natural and synthetic derivatives of vitamin A. The best known molecule of this class, all-trans-retinoic acid (RA),1 plays a physiological role in morphogenesis and cell differentiation. Its 13-cis-isomer (13-cis-retinoic acid, 13-cRA), which is better tolerated for systemic administration, is also used in the therapy of various dermatologic and neoplastic diseases (1–3).

RA (tretinoin), 13-cRA (isoretinoin), and other retinoids have been described to exert a number of suppressive activities on T cell functions, including a decrease in production of interleukins (IL, 4–15). However, immunostimulatory effects of 13-cRA and other retinoids on cellular and humoral immunity have also been reported (16–24). These observations indicate that the interactions of these molecules with the immune system are complex and not completely clarified. Nonetheless, the established and potential applications of retinoids in human therapy demand deeper investigation of their effects on the immune system, particularly at pharmacological concentrations.

In a previous article we reported that experimental autoimmune encephalomyelitis (EAE) was suppressed by RA (25). EAE is an autoimmune disease of the central nervous system (CNS) inducible in susceptible animals by immunization with myelin antigens or by passive transfer of sensitized T cells to syngenic recipients (26–34). EAE induced in Lewis rats has been used as a generic in vivo model of autoimmune disorders, because of the ease of detecting and quantitating disease activity and the consistency with which this rat strain develops a T cell–mediated delayed-type hypersensitivity-like autoimmune response (26, 27). In rodents, EAE is mediated by CD4+ , CD8−, and IL-2 receptor-positive T lymphocytes which induce perivascular inflammatory infiltrates in CNS by the end of the 2nd wk postimmunization (p.i.), in accordance with the onset of neurological signs, whereas encephalitogenic T lymphocytes can be recovered from peripheral lymphoid organs or peripheral blood, beginning 1 wk p.i. (30–34). In passive transfer EAE, CNS inflammatory infiltrates and neurological signs are present 5 or 6 d post-transfer of encephalitogenic T lymphocytes (30–34).

The suppression of EAE by RA indicates a possible suppressive activity of this drug on immune-mediated diseases, but its usefulness was limited by its toxicity, and therefore its possible immunosuppressive activity in the suppression of EAE was not studied further (25). However, 13-cRA, which has been demonstrated to retain most of the pharmacological activities of RA, is better tolerated for in vivo administration (1–3). This finding suggests that 13-cRA could represent an optimal retinoid for experimentation in autoimmune diseases, but the activity of pharmacological doses of this drug on T cell–mediated immunity has not been directly investigated (4).

For these reasons, we studied the in vivo effects of nontoxic pharmacological concentrations of 13-cRA in EAE, while the activity of the drug on T cell–mediated immunity was studied in splenocytes in vitro. We report that 13-cRA prevented EAE

1. Abbreviations used in this paper: CFA, complete Freund’s adjuvant; EAE, experimental autoimmune encephalomyelitis; IL-2sup, interleukin 2 supernatant(s); MBP, myelin basic protein; p.i., postimmunization; RA, all-trans-retinoic acid; 13-cRA, 13-cis-retinoic acid; RAR, RA receptor; SC, spleen cell; SI, stimulation index.


Immunosuppressive Activity of 13-cis-Retinoic Acid 1331
and suppressed T cell response during the effector phase of the immune response. The immunosuppression was functional and reversible, and was obtained at concentrations that can be achieved in human therapy, without inducing major side effects.

**Methods**

**Preparation of the antigens**

Myelin and myelin basic protein (MBP) were purified from guinea pig spinal cords (Pel Freeze Biologicals, Rogers, AR) according to the method of Norton and Poduslo (35) and Deibler et al. (36), respectively. The preparations were lyophilized, and stored at −20°C.

**Induction of EAE**

Female Lewis rats (175–225 g; Charles River Breeding Laboratories, Inc., Wilmington, MA) were immunized with an emulsion of either (a) 1 mg of guinea pig myelin, dispersed in 0.5 ml of complete Freund’s adjuvant (CFA) containing 3 mg/ml of *Mycobacterium tuberculosis* H37RA or (b) 50 μg of guinea pig MBP in 0.1 ml of CFA. The animals were injected intradermally in both hind foot pads. As “normal” control, six additional rats were sham-immunized with 0.5 ml of CFA only.

**Assessment of EAE**

Two experiments were designed in order to follow the clinical signs, and to describe laboratory parameters at day 12 p.i. In experiment 1, animals were assessed daily for weight and clinical signs for 3 wk. Clinical disease severity was graded on a scale of 1–5 as follows: 0, no signs; 1, tail paralysis; 2, tail paralysis and hind leg weakness; 3, hind leg paralysis; 4, tetraplegia; 5, death. In experiment 2, the animals were killed at day 12 p.i. in order to compare laboratory parameters and clinical signs. Spinal cord and brain were examined for the presence of perivascular cuffs. The intensity of the perivascular infiltrates was arbitrarily graded from 1 to 3 by two independent observers. Total DNA concentration was assayed in the spinal cord, according to Smith et al. (37), as a parameter of inflammatory cell infiltrates. At the time of sacrifice, peripheral blood samples were collected. Absolute and relative lymphocyte counts were carried out using a hemocytometer and Giemsa stained blood smears.

**Spleen cell (SC) response to Con A and antigens**

Spleens were collected at day 10 p.i. and passed through a stainless steel screen mesh. The single cell suspensions were separated from erythrocytes in a Ficoll-Hypaque density gradient centrifugation and washed in HBSS (Flow), resuspended in a final concentration of 2 × 10^6/ml of RPMI 1640 (Flow) supplemented with 5% heat-inactivated FCS (Flow Laboratories, Inc., McLean, VA), 1% L-glutamine, 1% Na-pyruvate (Flow Laboratories, Inc.), 1.25% Hepes buffer (Flow Laboratories, Inc.), 1% nonessential amino acids, 1% penicillin-streptomycin (Flow Laboratories, Inc.), and 5 × 10^-7 M 2-mercaptoethanol (2-ME). Proliferative assays in response to 6.25 μg/ml myelin and 50 μg/ml MBP and to 4 μg/ml Con A, were carried out in 96-microwell plates using 2 × 10^4 cells per well. [3H]Thymidine incorporation was measured by scintillation counting and the magnitude of the proliferative response was expressed as mean counts per minute (cpm) or as stimulation indexes (SI: stimulated culture cpm/unstimulated culture cpm).

**Preparation of IL-2-containing supernatant (IL-2sup)**

SC were removed from Lewis rats and cultured at 5 × 10^6/ml in presence of 4 μg/ml Con A as previously described (38). After 72 h the IL-2sup were removed, treated with 20 mg/ml α-methyl-mannoside, and frozen.

**IL-2 assay**

The IL-2 activity of the IL-2sup was assayed using the murine IL-2-dependent cell line, CTLL-2 (American Type Culture Collection, Rockville, MD) as previously described (39). Briefly 10^6 cells per well were added to 200 μl of culture medium containing increasing dilutions of IL-2sup. 48 h later the cultures were pulsed with [3H]thymidine for an additional 18 h. Data from two separate experiments were fitted using a program for analysis of dose-response curves (40). A possible CTLL-2 response to IL-2 was controlled in a separate assay and excluded: up to 50 U/ml of mouse IL-4 did not elicit CTLL-2 proliferation.

**Passive transfer of EAE**

Sensitized SC, harvested at day 10 from untreated immunized rats, were cultured in 24-well plates at a concentration of 5 × 10^5/ml with 4 μg/ml Con A for 3 d as previously described (41). After 72 h of culture, 4 × 10^5 viable SC per animal were injected i.p. to syngeneic naive recipients.

**13-cRA**

13-cRA was kindly provided by Dr. W. Bollag (Hoffmann-LaRoche, Basel). The powder was aliquoted in oxygen-free vials and stored at 4°C in the dark. Any procedure utilizing 13-cRA was carried out in dim light.

**In vivo studies.** On each day of treatment, the 13-cRA was suspended in corn oil and administered by gastric intubation, in two daily doses; matched controls received the vehicle only. In active EAE the animals were treated from days 6 to 11 p.i., whereas in passive EAE, from days 1 to 6 after the cell transfer. 13-cRA was suspended in corn oil at a concentration of 7.5 mg/ml. Each rat received 1 ml of suspension per 200 g of weight twice a day, in order to administer a total of 75 mg/kg per d. At day 5 of treatment (day 10 p.i.), sera from 37 immunized rats were collected at hours 1, 2, 4, 8, and 12 after the morning administration of the drug. To study the pharmacokinetics, 13-cRA concentrations were assayed in the serum samples by HPLC as previously described (42, 43), and the average serum concentration over 24 h was determined.

**In vitro studies.** 13-cRA was dissolved at different concentrations in dimethyl sulfoxide (DMSO); the stock solutions were then diluted in the culture medium at 0.01% DMSO final concentration. Control cultures were exposed to 0.01% DMSO only.

**Results**

**In vivo studies.** In control rats, the onset of EAE signs was observed at day 11 ± 1 p.i. (Fig. 1, Table I), whereas proliferative response to the Ag (SI = 4.5), was observed in SC beginning at day 6 (data not shown). In order to investigate the activity of 13-cRA on the effector mechanisms of the immune response in EAE, the animals immunized at day 0 with myelin were therefore treated from days 6 to 11 (Fig. 1, Table I), whereas the animals receiving cell transfer at day 0 were treated from days 1 to 6 (Table II). At day 5 of treatment, 75 mg/kg per d 13-cRA induced an average serum concentration during 24 h of 5.4±5.2 × 10^-6 M.

No major side effects were associated with 13-cRA treatment. In some treated animals a modest degree of weight loss (always < 10%) was observed (data not shown). No diarrhea or other signs of gastrointestinal irritation were noted.

As shown in Fig. 1 a delayed and less severe course of the disease was observed in animals receiving 13-cRA. Analysis at day 12 of the frequency of neurological signs and of the presence of inflammatory infiltrates in spinal cords showed that the disease was significantly suppressed (χ² test: P < 0.001; Table I). The onset of neurological signs, observed a few days after the suspension of the treatment, indicated that discontinuation of the therapy resulted in partial loss of the protective effects (Fig. 1). The highly significant suppression of DNA concentration in the spinal cords of the treated animals quantitatively con-
The characteristic lymphopenia described in rats during the course of EAE and during endogenous corticosteroid release (44–46) was observed in the vehicle-, but not in the 13-cRA-treated animals (Table I). In order to establish if the suppression of EAE occurred in presence of in vivo effects of the treatment on T cell functions, lymphocyte response to Con A was studied at day 10, immediately before the onset of the disease. At 8 h after the oral administration, when the 13-cRA serum concentration was 2.8±2.4×10^{-6} M, a lower proliferative response of lymphocytes from the 13-cRA-treated animals was observed (two-tailed Mann-Whitney U test, 2P = 0.02; Fig. 2).

**Table I. Effects of 13-cRA in Active EAE at Day 12**

<table>
<thead>
<tr>
<th>Treatment</th>
<th>Neurological signs†</th>
<th>Perivascular cuffs‡</th>
<th>DNA§</th>
<th>Lymphocyte counts∥</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>SC</td>
<td>SC</td>
<td>mg/mg</td>
<td></td>
</tr>
<tr>
<td>13-cRA</td>
<td>8/26 (0.8±0.1)</td>
<td>12/26 (0.7)</td>
<td>6.0±0.5</td>
<td>103±17</td>
</tr>
<tr>
<td></td>
<td>P &lt; 0.001</td>
<td>P &lt; 0.001</td>
<td>P &lt; 0.001</td>
<td>P &lt; 0.001</td>
</tr>
<tr>
<td>Oil</td>
<td>25/26 (2.2±0.1)</td>
<td>26/26 (1.7)</td>
<td>9.6±0.1</td>
<td>53±7</td>
</tr>
</tbody>
</table>

*75 mg/kg per d 13-cRA in corn oil or corn oil only from days 6 to 11 p.i.
†The numbers represent the frequency in each group, of animals with neurological signs or perivascular cuffs in the spinal cord. In parenthesis are reported the mean scores of the neurological signs or of the intensity of the inflammatory infiltrates (x^2 test).
‡Spinal cord mean DNA concentrations expressed as µg DNA/mg of protein ±2 SE. The mean DNA concentration in six sham-immunized animals was 5.6±0.2. (Student’s t test).
§Percentage ±2 SE of the values observed in sham-immunized animals (mean±2 SE of six observations = 4,416 ± 385). (Mann-Whitney test).

The in vivo activity of 13-cRA on the efferent limb of the immune response was also studied in passive transfer EAE. Animals treated with the vehicle developed neurological signs from days 6±1 to 9±1 after transfer, and perivascular cuffs were observed in spinal cords at day 11 (Table II). By contrast, animals receiving 13-cRA, from days 1 to 6 after cell transfer, developed neither neurological signs nor perivascular infiltrates in the spinal cord (Table II).

**In vitro studies.** In order to assess whether the suppression of EAE was due to a direct activity of the drug on T cell–mediated immunity, we studied in vitro the effects of 13-cRA on SC collected from untreated animals immunized with myelin or MBP. As shown in Table III, exposure of SC to 13-cRA concentrations equivalent to or less than those observed in vivo suppressed lymphocyte proliferation to antigens and to Con A in a dose-dependent manner. It is noteworthy that the background proliferations were not affected by the same concentrations of 13-cRA, indicating that up to 96 h in vitro exposure to the drug did not exert direct toxicity in lymphocytes. Moreover, exposure of the SC to 10^{-6} M 13-cRA during in vitro activation with Con A, before passive transfer, abrogated the

**Figure 1.** Effect of 13-cRA on the course of neurological signs in EAE. 13-cRA and corn oil were administered from days 6 to 11 after immunization for induction of EAE. Each point represents the mean of nine observations±SE. A delayed and less severe course of EAE is shown by the group receiving 13-cRA. The symptom score is reported in the text.

**Figure 2.** In vivo immunosuppressive activity of 13-cRA during the development of EAE. Each point represents quadruplicate proliferations of SC collected at day 5 of treatment (day 10 p.i.) and cultured for 48 h in presence of ConA (SE of < 15% cpm of the mean). When the serum concentration of the drug was 2.8±2.4×10^{-6} M, animals receiving 13-cRA (○) showed lower lymphocyte proliferation than the oil treated controls (●); mean±SE: 13-cRA = 252±47; OIL = 355±20; Mann-Whitney U test: P = 0.02.

**Table II. Effects of 13-cRA on EAE Passive Transfer**

<table>
<thead>
<tr>
<th>Treatment</th>
<th>In vitro*</th>
<th>Neurological signs†</th>
<th>Perivascular cuffs‡</th>
</tr>
</thead>
<tbody>
<tr>
<td>OIL</td>
<td>16/18</td>
<td>18/18</td>
<td></td>
</tr>
<tr>
<td>13-cRA</td>
<td>0/12</td>
<td>0/12</td>
<td></td>
</tr>
<tr>
<td>DMSO</td>
<td>0/12</td>
<td>0/12</td>
<td></td>
</tr>
</tbody>
</table>

*40×10^6 SC were injected i.p. in syngenic recipients.
†The numbers represent the frequency in each group, of animals with neurological signs or perivascular cuffs in the spinal cord.
‡Before transfer, the SC were cultured for 72 h with Con A, in presence of 0.01% DMSO or 10^{-6} M 13-cRA dissolved in 0.01% DMSO.
§From days 1 to 6 after cell transfer, 75 mg/kg per d of 13-cRA was administered in 1 ml of corn oil. Control animals received corn oil only.
**Table III. In Vitro Effects of 13-cRA on Ag- and Mitogen-induced SC Proliferation**

<table>
<thead>
<tr>
<th></th>
<th>DMSO^6</th>
<th>RA 10^-4 M</th>
<th>RA 10^-1 M</th>
<th>RA 10^-2 M</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>cpm</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Exp. 1 Medium*</td>
<td>4,420±567^6</td>
<td>5,140±943</td>
<td>2,920±348</td>
<td>6,740±1,130</td>
</tr>
<tr>
<td>Con A</td>
<td>319,000±13,400 (72.2)</td>
<td>114,000±9,140 (22.3)</td>
<td>95,500±15,000 (32.7)</td>
<td>70,600±5,870 (10.5)</td>
</tr>
<tr>
<td>Myelin (6.25 µg/ml)</td>
<td>21,000±3,940 (4.8)</td>
<td>11,400±2,530 (2.2)</td>
<td>10,200±1,790 (3.5)</td>
<td>11,500±712 (1.7)</td>
</tr>
<tr>
<td>Medium</td>
<td>11,600±3,010</td>
<td>9,630±565</td>
<td>14,700±1,290</td>
<td>5,490±1,030</td>
</tr>
<tr>
<td>Exp. 2 Medium</td>
<td>41,400±7,720 (3.5)</td>
<td>22,400±4,170 (2.3)</td>
<td>19,400±3,020 (1.3)</td>
<td>15,000±2,180 (2.73)</td>
</tr>
<tr>
<td>Con A</td>
<td>308,000±28,400 (26.4)</td>
<td>228,000±14,700 (23.7)</td>
<td>191,000±19,500 (12.9)</td>
<td>ND</td>
</tr>
<tr>
<td>Myelin (6.25 µg/ml)</td>
<td>41,400±7,720 (3.5)</td>
<td>22,400±4,170 (2.3)</td>
<td>19,400±3,020 (1.3)</td>
<td>15,000±2,180 (2.73)</td>
</tr>
<tr>
<td>Medium</td>
<td>8,450±2,030</td>
<td>6,390±1,520</td>
<td>6,650±1,460</td>
<td>7,660±1,390</td>
</tr>
<tr>
<td>Exp. 3 Con A</td>
<td>169,000±6,270 (20.0)</td>
<td>93,000±7,110 (14.5)</td>
<td>86,800±6,870 (13.1)</td>
<td>66,500±9,520 (8.7)</td>
</tr>
<tr>
<td>MBP (50 µg/ml)</td>
<td>37,800±4,520 (4.5)</td>
<td>22,400±3,070 (3.5)</td>
<td>23,100±4,790 (3.5)</td>
<td>15,000±2,310 (1.9)</td>
</tr>
<tr>
<td>Medium</td>
<td>2,540±422</td>
<td>3,200±545</td>
<td>2,610±278</td>
<td>2,650±4,170</td>
</tr>
<tr>
<td>Exp. 4 Con A</td>
<td>139,000±10,200 (54.6)</td>
<td>68,700±3,700 (21.4)</td>
<td>59,000±10,000 (22.6)</td>
<td>50,300±3,460 (18.9)</td>
</tr>
<tr>
<td>MBP (50 µg/ml)</td>
<td>14,800±2,000 (5.8)</td>
<td>2,830±411 (0.9)</td>
<td>3,410±483 (1.3)</td>
<td>2,810±292 (1.1)</td>
</tr>
</tbody>
</table>

* Myelin, MBP, and Con A were dissolved in the culture medium at 6.25, 50, and 4 µg/ml, respectively. † Each culture contained 0.01% DMSO. ‡ The values express cpm±SE of quadruplicate cultures. Stimulation indices (SI) are reported in parenthesis. The cells were collected from rats immunized with myelin in experiments 1 and 2, and with MBP in experiments 3 and 4.

The capacity of encephalitogenic lymphocytes to transfer EAE (Table II).

The previous experiments, indicating that T cell–mediated immunity is at least one of the targets of the immunological activity of 13-cRA, led us to study the effect of 13-cRA on lymphokine production by T cells. As expected, IL-2sup prepared in the presence of 10^-6 M 13-cRA showed a lower IL-2 activity, expressed as the proliferation of the IL-2–dependent T cell line CTLL-2, compared to control IL-2sup (P = 0.048, Fig. 3). However, the proliferation of the CTLL-2 induced by optimal dilutions of IL-2sup was not inhibited by the addition of 10^-6 M 13-cRA (data not shown). Suppression of IL-2 production, but not of IL-2 activity, is therefore one effect of 13-cRA on T cell–mediated immunity.

Finally, the effects of different times of exposure to 10^-6 M 13-cRA were examined in proliferating T lymphocytes during a standard 96-h stimulation assay in presence of Con A. 13-cRA reduced a SC proliferative response to the mitogen in a time-dependent manner, if it was added during the first 48 h of the assay, but did not show any effect if the Con A–stimulated SC were exposed to 13-cRA during the second 48 h (Fig. 4). This experiment demonstrates that exposure to 10^-6 M 13-cRA for up to 48 h does not affect viability of stimulated proliferating lymphocytes. Because under these experimental conditions at least one mitotic cycle is completed in 48 h, thymidine incorporation equivalent to 100% of the untreated cultures, indicate absence of antimitotic activity of the drug.

---

**Figure 3.** Suppression of IL-2 production in presence of 10^-6 M 13-cRA. The curves represent the response of the IL-2–dependent T cell line CTLL-2 to percent dilutions of IL-2 sup produced by SC in presence of 10^-6 M 13-cRA (RA IL-2sup, O), and to control IL-2sup (A). The dilution of RA IL-2sup exerting 50% of the maximal activity (ED50) was significantly higher (mean±SE = 1.65%±0.21) than the control ED50 (0.88%±0.11; P = 0.048).

**Figure 4.** Effects of different times of exposure of SC to 10^-6 M 13-cRA during a standard proliferation assay with Con A. Triplicate 96-h cultures were exposed to 13-cRA starting from the hour indicated on abscissa: each point represents the percentage proliferation of the 13-cRA exposed cultures in respect to control cultures not exposed to 13-cRA. (Δ-cpm of 13-cRA exposed cultures/Δ-cpm of DMSO-exposed cultures x100). 13-cRA suppresses the response to the mitogen in a time-dependent manner if added during the first part of the assay, but has no effect if added during the last 48 h.
Discussion

We have studied the effects of 13-cRA on in vivo and in vitro models of cellular immunity, at concentrations that are well tolerated in human therapy (1–3, 47–50). 13-cRA administration during the development of the effenter limb of the immune response significantly suppressed the clinical and histopathological signs of active EAE. Suppression was almost complete as long as the animals received 13-cRA, whereas discontinuation of the treatment resulted in a loss of the protective effect. However, passive transfer EAE was completely prevented and discontinuation of 13-cRA 6 d after passive transfer resulted in no late disease.

In these experiments, suppression of EAE was achieved using a treatment protocol that was not associated with major side effects and that induced serum concentrations equivalent to the highest reported to be tolerated in human therapy. Administration of drug boluses through gastric intubation permitted a precise control of the dosages, but did not allow an optimal absorption of the drug. For this reason and because of the high turnover rate of 13-cRA described in rodents (1–3), high oral dosages were required to achieve the desired serum concentrations. Preliminary experiments indicated that diarrhea and other signs of gastrointestinal intolerance (e.g., accelerated weight loss) developed in some animals by day 7 of 13-cRA therapy. For this reason a 6-d treatment regimen was selected. In humans, equivalent serum concentrations can be reached using much lower dosages of 13-cRA and such regimens are well tolerated even during chronic administration (47–50).

The response of SC to the T cell mitogen Con A was also inhibited during the treatment, indicating that the suppression of the disease occurred in presence of in vivo inhibition of T cell functions. The possibility that this inhibition was not functional but resulted from a direct lymphocytotoxic activity of the drug was excluded by the observation that, at day 7 from the beginning of the treatment, animals receiving 13-cRA had the same number of circulating lymphocytes as the "normal" controls which were sham-immunized with CFA only. The possibility that subclinical toxicity of 13-cRA may have induced release of endogenous corticosteroids was investigated using peripheral blood lymphocyte count as a marker: indeed, in rats exposed to stress, high levels of corticosteroids are secreted and a corresponding lymphopenia is usually observed (44–46, 51). In the present experiments, the rats treated with 13-cRA showed lymphocyte counts equivalent to the sham-immunized rats injected only with CFA, whereas the animals receiving corn oil showed the usual lymphopenia described in EAE (Table I, reference 46). This observation indicates that the 13-cRA administration did not induce relevant endogenous corticosteroid release, and therefore that the suppression of the disease was directly due to the treatment. The immunosuppressive activity of 13-cRA was also observed in vitro. Continuous exposure to 13-cRA concentrations equivalent to or less than those observed in vivo during EAE, suppressed Con A- and Ag-induced lymphocyte proliferation in a dose- and time-dependent manner, with maximal activity at 10⁻⁶ M (Table III), which decreased as a function of time when added after the lymphocyte activation (Fig. 4). This concentration prevented passive transfer of EAE by encephalytogenic lymphocytes (Table II) and reduced IL-2 production (Fig. 3) without lymphocytotoxic effect in vivo (Table I) as well as in vitro (Fig. 4). Taken altogether, the data reported in this paper indicate that pharmacological concentrations of 13-cRA are immunosuppressive and can prevent an ongoing T cell–mediated autoimmune disease even when administered exclusively during the development of the effenter limb of the immune response. An immunosuppressive activity intensive enough to control an ongoing immune response is shown also by cyclosporine A but not by cytotoxic drugs (52, 53). These drugs can suppress EAE if given prophylactically, but not if administered when the immune system has already mounted an effector response (53). It is likely that 13-cRA treatment does not specifically delete clones of Ag-responsive T cells, and the immunosuppressive activity is probably due to a nonspecific effect on one or more subpopulations of immunocompetent cells, which include suppression of IL-2 production. Indeed, the described activities of 13-cRA on T cell–mediated immunity and IL-2 production were observed stimulating an unselected SC population which included accessory cells such as macrophages and dendritic cells. In addition, suppressive activities of RA on accessory cell functions has been previously described (14, 54), suggesting that 13-cRA activity on IL-2 production as well as on T cell proliferation, could in part be indirect and mediated by an effect on accessory cells. The suppression of the T cell proliferative response as well as of IL-2 production, could be therefore due to a direct effect of 13-cRA on T-lymphocytes or could be indirect and mediated by other soluble factors produced by a number of immunocompetent cells. It is noteworthy, for example, that RA stimulates the production of transforming growth factor-β, one of the most powerful immunosuppressive cytokines, which is produced by many immunocompetent and nonimmunocompetent cells (55, 56). Nonetheless, the possibility of a direct effect of 13-cRA on IL-2 production by T lymphocytes is indirectly suggested by the reported inhibition by RA of diacylglycerol induced ornithine-decarboxylase activity, an early event that plays a key role in T lymphocyte activation (5–7). In addition, the described suppression of IL-2 production is consistent with the recent observation that another experimental retinoid, Ro 15-0778 (temarotene, Hoffmann-LaRoche, Basel), inhibits phytohemagglutinin-induced production of IL-2 and IFN-γamma in human T-lymphocytes (W. Bollag, personal communication). Temarotene has also been reported to exert a marked therapeutic activity on lichen planus, a human T cell–mediated dermatological disease (57). The possibility that 13-cRA acts on multiple targets of the immune activity must therefore be taken into account when results obtained under different experimental conditions are compared and may at least in part explain the large number of conflicting results reported in the literature (for review, see reference 4).

The similar pharmacological activities of RA and 13-cRA and the existence of an intracellular retinoid acid binding protein that binds both these retinoids (58) suggest that the two isomers could act through a common receptor. Five different RA receptors (RARs), each one encompassing multiple isoforms, have been so far described (59–67). At least three of these receptors bind RA as well as other natural and synthetic retinoids (59–62), including 13-cRA (63), although with less affinity. In addition, some degree of cis-trans isomerization to RA may in part contribute to the activity of 13-cRA. The RARs are differentially expressed in various tissues and exhibit different affinities for RA and other retinoids (59, 64), suggesting that they may have distinct roles in mediating a number of different activities of these molecules. Very few genes activated by the RARs are known so far (61, 64, 65), but it is noteworthy
that these receptors are highly conserved from rodents to humans and are expressed in both human and rat spleen, and that the optimal RA concentration inducing maximal transcription by the RARs is $10^{-6} M$ (59, 60, 63-66), the same nontoxic concentration that we have shown to be active on T cell-mediated immunity. In addition, RARs are part of a superfamily of nuclear receptors that also mediate the activity of steroid and thyroid hormones (67), supporting the hypothesis that RA functions in a fashion analogous to these hormones. Moreover, it must be emphasized that steroid and thyroid hormones can repress gene expression as well as activate it (67). It is possible therefore to hypothesize that, like glucocorticoids, 13-cRA exerts suppressive activity on T cell-mediated immunity through a receptor whose expression varies in different cell populations and under different experimental conditions. Nonetheless, the observations presented in this article establish that, in an in vivo mammalian system, the net result of 13-cRA activity is a suppressive effect on T cell-mediated immune response, and that this activity is intensive enough to suppress an ongoing immune response at nontoxic concentrations which may also be reached in human therapy. Considering that the serum concentrations of 13-cRA induced in this study can be chronically maintained in human therapy with minor side effects (1-3, 47-50), the experimental use of 13-cRA also in human chronic T cell-mediated autoimmune diseases can now be proposed.

In addition, the prevention of EAE, a model of human T cell-mediated disease of the CNS (27), and the excellent bioavailability in the CNS of retinoids (68, 69), suggest that multiple sclerosis patients could constitute an appropriate population for a phase 1 clinical trial.

Acknowledgments

The authors wish to thank Dr. Laura Raimondi for the HPLC assay of 13-cRA and Dr. Dale McFarlin and Dr. Richard McCarron for helpful discussion. The authors are also grateful to Dr. Michael Sporn for help in the revision of the manuscript.

This study was supported by a grant of the Italian National Research Council. Dr. Massacesi was a recipient of a fellowship of the Italian National Research Council.

References


**Immunosuppressive Activity of 13-cis Retinoic Acid**

1337